CSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI® in IgA Nephropathy
Provided By PR Newswire
Last update: Apr 29, 2025
European Commission converts conditional approval of FILSPARI (sparsentan) into standard marketing authorization for the treatment of IgA Nephropathy (IgAN)
Read more at prnewswire.com34.51
+0.02 (+0.06%)
Find more stocks in the Stock Screener
TVTX Latest News and Analysis
3 days ago - By: Chartmill
